XML 63 R38.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaborative and Other Relationships (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0 million varies upon the following events, as summarized in the table below:
After LUNSUMIO Approval until the First Threshold Date | 37.5 | %
After First Threshold Date until the Second Threshold Date | 35.0 | %
After Second Threshold Date | 30.0 | %
Pretax profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies upon the following events, as summarized in the table below:
Until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from anti-CD20 therapeutic programs | Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Royalty revenue on sales of OCREVUS |  | $ | 283.6 |  |  | $ | 252.3 |  |  |  |  |
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO |  | 112.5 |  |  | 143.2 |  |  |  |  |
Other revenue from anti-CD20 therapeutic programs |  | 3.4 |  |  | 3.9 |  |  |  |  |
Total revenue from anti-CD20 therapeutic programs |  | $ | 399.5 |  |  | $ | 399.4 |  |  |  |  |
Summary of activity related to Aducanumab collaboration | A summary of development expense and sales and marketing expense related to our initial ADUHELM Collaboration Agreement is as follows:
|  |  | For the Three Months Ended March 31, |  |
(In millions) |  |  |  | 2022 |  |  |  |
Total ADUHELM Collaboration development expense |  |  |  | $ | 44.2 |  |  |  |  |
Biogen's share of ADUHELM Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  |  |  | 24.3 |  |  |  |  |
Total sales and marketing expense incurred by the ADUHELM Collaboration Agreement |  |  |  | 95.0 |  |  |  |  |
Biogen's share of ADUHELM Collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income |  |  |  | 50.9 |  |  |  |  |
Summary of activity related to the UCB collaboration | A summary of development expense related to the UCB collaboration agreement is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Total UCB collaboration development expense |  | $ | 18.3 |  |  | $ | 17.6 |  |  |  |  |
Biogen's share of UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 9.2 |  |  | 8.8 |  |  |  |  |
Summary of Activity Related to Denali Therapeutics Collaboration | A summary of development expense related to this collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Total Denali collaboration development expense |  | $ | 16.6 |  |  | $ | 14.9 |  |  |  |  |
Biogen's share of Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 10.0 |  |  | 8.9 |  |  |  |  |
Summary of Activity Related to BAN2401 and Elenbecestat Collaboration |
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Total development expense incurred by the collaboration related to the advancement of LEQEMBI |  | $ | 107.9 |  |  | $ | 77.0 |  |  |  |  |
Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 54.0 |  |  | 38.5 |  |  |  |  |
Total sales and marketing expense incurred by the LEQEMBI Collaboration(1) |  | 10.5 |  |  | 15.9 |  |  |  |  |
Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income(1) |  | 5.3 |  |  | 8.0 |  |  |  |  |
(1) Beginning in the first quarter of 2023 reimbursement to Eisai for our share of U.S. LEQEMBI selling, general and administrative expense is recognized in revenue from LEQEMBI Collaboration within our condensed consolidated statements of income.
Summary of Activity Related to Sangamo Therapeutics | A summary of development expense related to this collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Total Sangamo collaboration development expense |  | $ | 5.1 |  |  | $ | 8.3 |  |  |  |  |
Biogen's share of Sangamo collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 2.3 |  |  | 5.5 |  |  |  |  |
Summary of Activity Related to Sage Therapeutics | A summary of development and sales and marketing expense related to this collaboration is as follows:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2023 |  | 2022 |  |  |  |
Total Sage collaboration development expense |  | $ | 34.8 |  |  | $ | 38.7 |  |  |  |  |
Biogen's share of Sage collaboration development expense reflected in research and development expense in our condensed consolidated statements of income |  | 17.4 |  |  | 19.4 |  |  |  |  |
Total Sage sales and marketing expense incurred by the collaboration |  | 38.2 |  |  | 18.4 |  |  |  |  |
Biogen's share of Sage collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income |  | 19.1 |  |  | 9.2 |  |  |  |  |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Denali Therapeutics Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Sage Therapeutics + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to Sangamo Therapeutics + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToSangamoTherapeuticsTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to the UCB Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration